Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation-Reference-Cited by-同舟云学术

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

Published:2013-06-06 Issue:23 Volume:121 Page:4655-4662
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Ravandi Farhad¹,Alattar Mona Lisa¹,Grunwald Michael R.²,Rudek Michelle A.³,Rajkhowa Trivikram²,Richie Mary Ann¹,Pierce Sherry¹,Daver Naval¹,Garcia-Manero Guillermo¹,Faderl Stefan¹,Nazha Aziz¹,Konopleva Marina¹,Borthakur Gautam¹,Burger Jan¹,Kadia Tapan¹,Dellasala Sara¹,Andreeff Michael¹,Cortes Jorge¹,Kantarjian Hagop¹,Levis Mark²

Affiliation:

1. Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX; and

2. Division of Hematological Malignancies,

3. Division of Chemical Therapetuics, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD

Abstract

Key Points Azacytidine and sorafenib are effective in patients with relapsed and refractory FLT3-mutated AML.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/121/23/4655/1366002/4655.pdf

Reference49 articles.

1. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.;Nakao;Leukemia,1996

2. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.;Kottaridis;Blood,2001

3. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.;Fröhling;Blood,2002

4. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.;Thiede;Blood,2002

5. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group.;Abu-Duhier;Br J Haematol,2000

Cited by 336 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia;Expert Review of Hematology;2024-05-20

2. Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease;British Journal of Haematology;2024-05-09

3. Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors;Current Treatment Options in Oncology;2024-05-02

4. Therapeutic biomarkers in acute myeloid leukemia: functional and genomic approaches;Frontiers in Oncology;2024-02-12

5. Acute myeloid leukemia patients with high-risk karyotypes benefit from decitabine in combination with modified CAG;2024-01-08